The aim of this study was to determine whether pathologically proven central or lateral lymph node (LN) metastasis (pN1a or pN1b) could affect ablation success and recurrence after high-dose radioactive iodine (RAI) ablation. We also sought to identify the risk factors for long-term recurrence in patients with papillary thyroid carcinoma (PTC). Materials and Methods: A total of 277 patients with pN1 disease who had undergone high-dose RAI ablation (5.55 GBq) between 2000 and 2006 were included in this retrospective study. We compared the ablation success rate and the recurrence rate between patients with pN1a and pN1b disease. Univariate and multivariate analyses were performed to identify the risk factors for recurrence. Results: The median duration of follow-up was 10.2 years. The overall ablation success rate was 64%, and the ablation success rate in the pN1b group (49%) was lower than in the pN1a group (74%). The overall recurrence rate was 23%, and the recurrence rate in the pN1b group (30%) was higher than in pN1a group (18%). A higher ratio of metastatic LNs, a higher level of pre-ablation thyroglobulin, and ablation failure were significant risk factors for recurrence by multivariate analysis. Conclusion: Patients with pN1b disease experienced a lower ablation success rate and a higher recurrence rate than patients with pN1a disease. However, a higher ratio of metastatic LNs, a higher level of pre-ablation thyroglobulin, and ablation failure were stronger risk factors than the pathological N stage for long term recurrence in patients with node-positive PTC.
Introduction
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma. Lymph node (LN) metastasis is frequently found in up to 70% of patients, and recurrence may occur in more than 30% of cases, although the disease-related mortality for PTC is not high. 1) Previous studies have identified several risk factors for recurrence in patients with PTC. 1, 2) However, the impact of the location of metastatic LNs on mortality and recurrence is controversial. A complicating factor is the difficulty encountered by surgeons and pathologists when trying to precisely locate metastatic LNs during surgery or in surgical specimens. The American Joint Committee on Cancer (AJCC) has subdivided patients with positive neck nodes into N1a and N1b groups. N1b status is associated with a worse re- regardless of the location of the metastatic LNs. 4) As suggested by the recent ATA guideline, the risk of recurrence can vary depending on the specific characteristics of the metastatic LNs, such as size, number, and extranodal extension, in patients with neck node-positive PTC. 5, 6) Compared with previous recommendations, recent ATA guidelines have tended to not to consider the presence of regional neck node metastasis to be an indicator of a worse prognosis. 4) Since Mazzaferri 7) reported that RAI ablation was effective in reducing recurrence in patients with PTC, radioactive iodine (RAI) therapy after surgery has been a standard procedure for the ablation of remnant thyroid tissue and for the treatment of iodine-avid metastasis for over 50 years. Prior to the 2009 ATA guidelines, a dose of 5.55 GBq I-131 was commonly applied to patients with neck node metastasis, regardless of the location of the involved lymph nodes. 4) Although recent papers have suggested using a lower activity I-131 for remnant ablation or adjuvant therapy after total thyroidectomy, controversy still exists regarding the optimal strategy of RAI therapy according to the status of metastatic LNs in patients with node-positive PTC. [8] [9] [10] [11] Given the controversy surrounding the impact of LN metastasis on the outcome of patients with PTC, the aim of this study was to determine whether different locations of metastatic LNs had an impact on the success of ablation therapy or the rate of recurrence.
Additionally, we attempted to identify the risk factors for long-term recurrence in patients with PTC and pathologically-proven neck node metastasis. Board, and the requirement for written informed consent was waived.
Materials and Methods

Patients
Radioactive Iodine Ablation Protocol
All patients underwent total thyroidectomy with central and/or lateral neck dissection for PTC followed by RAI ablation therapy. To induce a hypothyroid state, levothyroxine (T4) was discontinued for at least 4 weeks with triiodothyronine (T3) replacement for the first 2 weeks. A low-iodine diet was also prescribed for all patients at least 2 weeks before RAI ablation. Evaluation for Successful Ablation 
Clinical Endpoints and Follow-Up
To evaluate the prognostic value of clinical and pathologic parameters, recurrence was chosen as an endpoint. RFS was calculated from the date of RAI ablation to the date of recurrence or the last follow-up.
Statistical Analysis
Statistical analysis was performed using MedCalc for Windows, version 13.3.0.0 (MedCalc Software, Mariakerke, Belgium). All patients were divided into 2 groups, the pN1a group and the pN1b group.
Comparison of categorical variables between the two groups was performed with a chi-square test, and continuous variables were compared by Student t-test. The Kaplan-Meier method and the log-rank test were used in the survival analysis for RFS between the two groups. The Cox proportional hazards model with forward method was used to assess the potential independent effects of clinicopathologic parameters for RFS. A p value ＜0.05 was considered to be statistically significant.
Results
Clinical and Pathologic Characteristics
The clinical and pathologic characteristics of 277 patients with PTC are shown in Table 1 . The median duration of follow-up was 10.2 years (range, 0.8-
years)
. Among the 277 patients, 167 (60%) patients were classified as the pN1a group, and 110 (40%) patients were classified as the pN1b group. Age was not significantly different between the two groups.
The mean number of dissected LNs was 15±13.
More LNs were dissected (27±14 vs. 7±4, p＜ 0.001) and a higher number of metastatic LNs were identified (8±6 vs. 3±2, p＜0.001) in the pN1b group than in the pN1a group. The ratio of metastasis per dissected LN was higher in the pN1a group. The proportion of male patients and the pre-ablation s-Tg levels were higher in the pN1b group. The proportion of patients who showed I-131 uptake outside of the thyroid bed (LN or distant organ) on post-therapy I-131 WBS was also higher in pN1b group.
Ablation Success Rate and Recurrence Rate
The overall ablation success rate was 64% (n= 177/277) and was higher in the pN1a group than in the pN1b group (74% vs. 49% p＜0.001, Fig. 1 ). The currence, such as local (thyroid bed), regional (central or lateral neck LN), and distant metastasis. There was no significant difference in recurrence site between the pN1a group and pN1b group (p=0.645).
The recurrence rate in the pN1b group (30%, 33/110) was much higher than that in the pN1a group (18%, 30/167, p=0.028, Fig. 2 ). The time to recurrence was longer in the pN1a group than that in the pN1b group (mean 33.7 months vs. 26.7 months), although there was no statistically significant difference (p=0.357). Accordingly, the RFS was shorter in the pN1b group than in the pN1a group (mean 129 months vs. 153 months, p=0.013, Fig. 3 ). Thyroid cancer-related death was observed in 2 patients (1.2%) in the pN1a group and 5 patients (4.5%) in the pN1b group (p=0.178).
Univariate and Multivariate Analyses for Recurrence-Free Survival
Univariate and multivariate analyses for RFS were performed using various clinical and pathologic parameters ( 
Discussion
In our series of 277 subjects who underwent surgery followed by RAI ablation using high dose (5. Meer et al. 9) reported that the presence of lateral metastatic LNs was correlated with a higher recurrence rate and lower disease-free survival than central metastatic LNs. Some other studies have also reported that PTC patients with pN1b disease had poorer RFS than pN0/Nx and pN1a patients. 13, 14) In the current study, recurrence occurred in a significant proportion of patients, including 30% in the pN1b group (30%) and 18% in the pN1a group (18%), although they received high-dose (5.55 GBq) RAI therapy. Furthermore, the ablation success rate was lower and the cumulative number of RAI therapy and recurrence rates were higher in patients with pN1b than in those with pN1a disease. Therefore, application of lower dose such as 1.1 GBq I-131 in patients with N1b does not seem to be reasonable approach.
In the current study, patients who were administered According to the AJCC staging system, 3) age is an important factor in PTC staging. Younger node-positive patients (age＜45) are classified as having stage I disease, whereas older node-positive patients (age ≥45) are classified as either stage III or stage IV disease. Smith et al. 2) reported that disease specific survival was worse for older patients with pN1b PTC.
Furthermore, the presence of node metastasis did not significantly affect survival for younger patients, regardless of the location. Sabra et al. 11) reported that RAI ablation using more than 3.7 GBq of I-131 was unlikely to improve therapeutic response in younger patients with pN1b disease. In the current study, binary classification by age (older than 45 years) was not a significant risk factor for recurrence in node-positive PTC patients. In a subgroup analysis, however, the location of metastatic LNs was a significant risk factor for recurrence in the older age group (p=0.044), but not in the younger age group (p=0.175). The overall ablation success rate of 64% in the present study group was lower than those of recent randomized trials, where success rates ranged from 90-94%. 10, 18) Several factors affecting ablation success rates have been previously reported such as surgical completeness, the characteristics of the enrolled patient population, the definition of ablation success and the differences in iodine diet conditions. However, our differing results may also be due to the application of different criteria for remnant ablation success used in this study. One study evaluated the success of remnant ablation based on neck US and s-Tg levels or diagnostic WBS in patients with detectable Tg-Ab. 18) In the present study, successful ablation was defined as a s-Tg level less than 2 ng/mL, negative or only negligible faint bed uptake on diagnostic WBS, and negative neck US at first evaluation, these more stringent criteria may explain the lower ablation success rate. Furthermore, this study was performed in a high-iodine intake area, and excessive dietary intake of iodine can also result in poor ablation outcomes. Sohn et al. 19) reported that the ablation rate significantly decreased as the urinary iodine excretion Thus, the results may differ from those of patients who underwent prophylactic central neck dissection.
In summary, our results suggest that more aggressive therapy, such as RAI ablation, using a higher dose of I-131 may be needed in PTC patients with pN1b disease than in those with pN1a disease.
Consideration should not only be given to the pathological N stage but also to the ratio of metastatic LNs and pre-ablation s-Tg levels when determining the optimal therapeutic strategy.
In conclusion, patients with pN1b PTC experienced a lower ablation success rate, a higher recurrence rate and shorter RFS than patients with pN1a PTC.
However, a higher ratio of metastatic LNs and a higher level of pre-ablation s-Tg were stronger risk factors than the pathological N stage for long-term recurrence in patients with node-positive PTC.
